Navigation Links
Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Date:4/30/2008

price), for an aggregate potential exercise price of $27.1 million. The investor will also receive a second warrant which entitles it to purchase $67.5 million of additional notes and warrants. The Company will have the ability to accelerate the termination date of the warrant in the event that the Company meets one of two potential milestone events as well as other conditions to be more fully described in the Company's Form 8-K for this transaction.

Up to $5,250,000 in principal amount of existing 9% Convertible Senior Notes due 2012, along with all warrants issued in connection with such notes, may be exchanged for an equal amount in principal of new securities in the offering.

The Company intends to use the net proceeds from this offering to retire the remaining balance of the 2008 Senior and Junior Convertible Notes due June 15, 2008 of approximately $10.8 million, to acquire access to Bayer-Schering's phase III "FIT" trial data to submit an sBLA application for label expansion of Zevalin in the US and for general working capital.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the offering.

A prospectus supplement relating to the Preferred Stock and Convertible Notes to be issued in the offering will be filed with Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in whi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
2. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
3. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
4. Cell Therapeutics, Inc. Announces Filing of Form 10-K
5. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
6. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
7. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
8. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
9. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
11. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers found that ... identifies patients with bone fragility fracture when today,s ... people worldwide are at risk of fracture for ... bone strength test, the DEXA bone density scan. ... for Bone and Mineral Research Annual Conference (ASBMR) ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
Breaking Biology Technology:ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced that BioSpecifics, President, Tom Wegman, will ... Health Care Conference on Monday, March 7, 2011, at ... Boston, Massachusetts. A live webcast of the ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... company,s headquarters in Rockville, Maryland, on Monday, March 7, ... to $179 million. The Office of Biomedical Advanced Research ... Assistant Secretary for Preparedness and Response at the U.S. ...
... New research from the University of Pennsylvania demonstrates a ... atomic-scale material that has promising applications in a variety ... Nobel Prize in Physics. As explained in a ... to create high-quality graphene that is just a single ...
Cached Biology Technology:Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 2Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 3Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 4Penn physicists develop scalable method for making graphene 2Penn physicists develop scalable method for making graphene 3
(Date:9/16/2014)... show its extravagant, colorful tail feathers in courtship of ... a special camera developed by an engineer at Washington ... swordtail fish choose their mates based on a similar ... at Austin used a bioinspired polarization camera developed by ... engineering at Washington University, to make the discovery. His ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... ethical choices such as buying clothing not made in ... and bringing their own bags when they go shopping? ... of Consumer Research , ethical consumption is motivated by ... unethical practices into action. , "Advocates of ethical consumerism ... costs of the products they choose, but unfortunately only ...
Breaking Biology News(10 mins):Camera developed at WUSTL sheds light on mate choice of swordtail fish 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Why are consumers willing to spend more money on ethical products? 2
... land managers on the Olympic Peninsula joined in an ... the University of Washington to develop a set of ... for resiliency and sustainability in the face of a ... of vegetation, hydrology, roads, fish, and wildlife on the ...
... In the chemistry of the living world, a pair of ... genetic code, they provide all organisms with a mechanism for ... vital to living systems. Yet according to John ... Informatics, at Arizona State University,s Biodesign Institute, it may not ...
... databases is just the tip of the iceberg in online ... focus to social networks and today a number of Facebook ... and other armed groups that have been included in the ... in a new study conducted by Prof. Gabriel Weimann of ...
Cached Biology News:Partnership yields options for adapting to climate change on the Olympic Peninsula 2Simpler times: Did an earlier genetic molecule predate DNA and RNA? 2Simpler times: Did an earlier genetic molecule predate DNA and RNA? 3Simpler times: Did an earlier genetic molecule predate DNA and RNA? 4A 'friend' request from al-Qaida 2
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
...
Guanine nucleotide-binding protein G(k), alpha subunit...
Biology Products: